Loading
Latest filing published 09 Jul 2021 for Trillium Therapeutics Inc., €940. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Robert Uger, listed as senior executive, appears in our data through filings on Trillium Therapeutics Inc. shares, published by SEC (Form 4). Over a trading history stretching from 7 May 2021 to 7 July 2021, the count stands at 3 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 9 July 2021, the filings show an option exercise worth €940 in Trillium Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations